Company
Synairgen PLC
LON:SNG
Synairgen PLC is a UK-based respiratory company focused on drug discovery and the development of SNG001 (inhaled interferon beta) as potentially the first host-targeted, broad-spectrum antiviral treatment delivered directly into the lungs for severe viral lung infections.
149 stories · page 1 of 2
Synairgen says SPRINTER trial data published, to push ahead with SNG001
Topline results were released earlier in the year
Synairgen encouraged by NIH Covid study data
America's National Institutes of Health oversaw the ACTIV-2 study to assess SNG001’s impact on home-based sufferers of the virus
Synairgen assessing three clinical options for antiviral drug
"We continue to be excited about the potential of SNG001," Richard Marsden, chief executive of the drug discovery and development company said
Synairgen to present data showing drug lowers risk of long Covid symptoms
For fatigue, the relative risk reduction was 35.4%, for shortness of breath 28.3% and for loss of smell and/or taste 61.4%
Synairgen reports positive data from respiratory viral infection drug
There was also a significant difference in the proportion of patients with detectable virus in their sputum by day seven
Synairgen to play key role in respiratory viral infection study
It will be working with US pharma group Janssen and the University of Southampton's clinical trial unit
Synairgen 'working in haste' to plan new lung infection trials
The drug developer reported result showing it had a year-end cash balance of £33.8mln
Synairgen data analysis provides 'strong clinical rationale' to continue work on Covid treatment
A review of phase III data has identified a group of virus sufferers that could potentially benefit from SNG001
Synairgen to present data from phase III Covid trial at leading industry conference
It has been selected for two sessions at the ATS 2022 gathering in San Francisco next month
Synairgen says there are 'ongoing discussions' to find new trial for lead asset after US study is halted
The ACTIV-2 evaluation was halted following the “significant shift in the nature of the pandemic"
Synairgen updates on SNG001
It provided guidance on work being carried out by the US National Institutes of Health and shared lab results that revealed "potent antiviral activity” against Delta and Omicron of its lead asset
Synairgen phase III results disappoint
“[The] improvement in patient care may have compromised the potential of SNG001 to show a clinical benefit in respect of the endpoints for this study, which were not met," said chief executive Richard Marsden
Synairgen ties up with Ashfield Engage as it advances Covid-19 treatment
"We are excited to be working with Ashfield Engage given their relevant COVID-19 experience and are confident they understand our needs and values as we build the optimal team," said
Synairgen presents data on antiviral activity of lead asset
The updates were given to the European Scientific Working Group in Influenza conference
Synairgen shares rise 7% after clinical trial update
The shares are still some way shy of finnCap's valuation
Synairgen recruits all 610 patients for final stage trial on COVID-19 drug
The trial has been granted Fast Track status from the US Food and Drug Administration and was classified as an Urgent Public Health study by the UK's National Institute for Health Research
Synairgen COVID-19 treatment gets green light for US government-sponsored Phase III trials
The ACTIV-2 trial tests the treatment in non-hospitalised adults experiencing mild to moderate COVID-19 and is sponsored by the US NIAID
Synairgen appoints chief regulatory officer in preparation for SNG001 regulatory submissions
"His experience and expertise in global regulatory strategy will be invaluable," said chief executive Richard Marsden
Synairgen says COVID-19 treatment trials going well; expects top line results early next year
The drug is seen as having potential value not only for hospitalised COVID-19 patients, but also for other severe viral lung infections caused by cold and flu viruses, and for government stockpiling to prepare for future potential pandemics
Archive
Small cap movers:Synairgen soars after encouraging COVID-related lab tests while the tide turns for SIMEC Atlantis
A look at some of the week's big movers in the small cap world
Synairgen says COVID treatment has shown potent antiviral activity against two variants
"In vitro” experiments were carried out to assess the drug’s potential efficacy against the Kent and South African mutations
Synairgen hails exceptional progress over 2020 towards treatment for COVID-19
The company said a Phase III trial of its SNG001 candidate was initiated last year with the results expected in the second half of 2021
Synairgen price target maintained at 505p by broker finnCap
Treatment led to a threefold likelihood of recovering
Synairgen phase II data points to potential of its drug in severe Covid
Chief executive Richard Marsden said of the read-out: “It increases our conviction in the approach we have taken to conduct an international phase III trial in hospitalised patients requiring supplemental oxygen, which is scheduled to read
Synairgen says US government phase II/III trial of inhaled COVID-19 treatment has begun dosing
The sub-study will evaluate drug SNG001’s potential in people with mild to moderate COVID-19 symptoms not yet requiring hospitalisation
Archive
Maintel holds the line despite the second lockdown
A look at some of the major movers in London on Monday
Synairgen says inhaled drug included in a major US government-sponsored coronavirus trial
The drug discovery and development specialist said researchers will assess SNG001’s potential to help patients not yet requiring hospitalisation
Synairgen focuses on potentially breakthrough coronavirus treatment now at last stage of trials
The company has been developing a treatment for chronic lung disease in-house now tested for COVID-19
Synairgen completes recruitment of patients for home coronavirus trial
“The trial is both a test of the drug, and a test of how technology can be utilised to deliver and manage the administration"
Coronavirus: Synairgen starts final phase of treatment trials days after UK introduces new regimen
A recap on the current therapies available for COVID-19 patients
Synairgen phase III trial of potentially breakthrough coronavirus treatment now underway
“We believe this trial presents an opportunity for a significant UK scientific breakthrough and, if given the right support, our drug could rapidly assist with the global crisis," said chief executive, Richard Marsden
Archive
Proactive news headlines: Synairgen, Scancell, EQTEC, Great Western Mining, Trident Royalties ...
A glance at some of the day's highlights from the Proactive Investors newswire
Synairgen speeds up the trial of potential coronavirus treatment
“SNG0011 is one of the few potential treatments to have shown efficacy against severe viral lung infections such as COVID-19"
Archive
FTSE 100 closes end of week lower as markets lack direction
Britain's benchmark of leading shares closed down nearly 22 points at 6,529
Archive
Small Cap Movers: Pfizer’s positive vaccine news prompts stocks sell-off
A look back at some of the more interesting stories from London's junior market over the past week
Archive
Proactive news headlines: Synairgen, Alien Metals, Sensyne Health, Vast Resources …
A glance at some of the day's highlights from the Proactive Investors newswire
Synairgen says inhaled drug formulation could treat patients suffering with coronavirus and flu
Patients who were given the company's inhaled formulation of interferon beta-1a had greater odds of improvement and recovered more rapidly than those given a placebo
Archive
Small Cap Movers: ‘Ten-baggers’ Synairgen, Alien Metals keep up impressive share price runs
A look back at some of the more interesting stories from London's junior market this week
Synairgen gets house broker upgrade after impressive fundraise
"We now have the resources to be able to rapidly progress this potential breakthrough treatment
Synairgen successfully closes £80mln share sale to fund pivotal trial and manufacturing of breakthrough COVID-19 drug
The company could receive a further £7mln from an open offer of stock to investors that did not take part in the placing in which shares were sold at 175p each
Proactive news headlines: Synairgen, Westminster Group, Jersey Oil & Gas, Powerhouse Energy...
A glance at some of the day's highlights from the Proactive Investors newswire
Synairgen teams up with Clinigen to provide a managed access programme for Covid treatment
Chief executive Richard Marsden said the Synairgen team was “working tirelessly to progress SNG001 through the required clinical and regulatory channels"
Synairgen submits patent application for SNG001 treatment
The application covers the use of SNG001 to treat virus-induced exacerbations in patients suffering from COPD
Synairgen says interim readout supportive of coronavirus programme
The analysis of SNG001 revealed it was well tolerated in this older population studied and that lung antiviral responses were “significantly enhanced”
Demand for healthcare stocks similar to late 90s tech boom, says analyst
Turner Pope's Andy Thacker said there has been a boom in investor demand for firms in the biotech and health spaces since the onset of the coronavirus pandemic
Synairgen boss says SNG001 results “a clearer signal than we could have dared hope for”
On Monday, the company reported that patients who received its treatment had a 79% lower risk of developing severe disease compared to those given the placebo
Synairgen targets in-home patients for next phase of SNG001 trial
On Monday morning, the company unveiled results from a clinical trial which showed that patients that received the treatment had a 79% lower risk of developing the severe version of the disease than those taking a placebo
Archive
Proactive news headlines: Synairgen, Touchstone Exploration, Shanta Gold, ReNeuron …
A glance at some of the day's highlights from the Proactive Investors newswire
Synairgen rockets as trial results could signal "major breakthrough" in treatment of severely ill COVID-19 patients
People who received SNG001, an inhaled formulation of interferon beta, had a 79% lower risk of developing the severe disease compared to those given the placebo, the data revealed
Synairgen says coronavirus (COVID-19) trial to be expanded nationally
Sufferers will receive the inhaled medication in their homes rather than at hospital
Synairgen completes hospital recruitment for coronavirus trial
Synairgen said a successful outcome for the trial would provide valuable information for the continued development of SNG001, an inhaled formulation of interferon-beta-1a, or coronavirus patients
Synairgen gets green light for home study of coronavirus inhaled drug; top line data expected in July
The idea is to treat sufferers earlier in the illness – within three days of developing symptoms
Synairgen surges as it extends SNG001 study to coronavirus patients in home environment
The aim of the extension is to dose patients with the treatment earlier in the infection cycle before severe lower respiratory tract symptoms develop
Archive
Small cap movers: AIM-listed companies raise £500mln in less than a month to cope with coronavirus crisis
A look back at some of the more interesting stories from London's junior market this week
Synairgen jumps as SNG001 trial on coronavirus patients labelled as an Urgent Public Health study
The company revealed on March 31 that the first patient was dosed in the double-blind, placebo-controlled trial at the University Hospital Southampton NHS Foundation Trust.
Synairgen starts dosing patients in coronavirus trials
"We are delighted to get this trial underway with the dosing of the first patient," said Richard Marsden, the chief executive officer of Synairgen
Synairgen raises £14mln in placing to fund coronavirus trial
The funding took place via firm and conditional placings carried out on Wednesday through a bookbuild by broker finnCap
Why the coronavirus crisis might not be as bad as 2008; and why it might be worse
Markets are pausing for breath, trying to work out what's coming next
Archive
Proactive news snapshot: Synairgen, Ergomed, Westminster Group, Union Jack Oil …
A glance at some of the day's highlights from the Proactive Investors newswire
Synairgen to start COVID-19 trial of lead drug imminently
SNG001 is an inhaled formulation of interferon-beta-1a and is currently being developed to treat people with chronic obstructive pulmonary disease
Coronavirus: Small biotechs buck market trend as search for lung infection relief intensifies
All are in one way or another working on drugs either to help cure lung disease or alleviate the symptoms.
Archive
Proactive snapshot: Synairgen, Bushveld Minerals Limited, KR1
A look at some of the top stories from the Proactive newswire on Monday
Synairgen set for a busy winter
"The company has made good progress on its inhaled broad-spectrum antiviral candidate IFN-beta, designed to treat viral chest infections in patients with COPD."
Synairgen to share encouraging data
The company’s chief scientific officer, Dr Phillip Monk, will deliver the update on Sunday (Sept 29) to the European Respiratory Society International Congress being held in Madrid
Archive
Proactive news snapshot: Synairgen, Active Energy, Arc Minerals...
A glance at some of the day's highlights from the Proactive Investors newswire
Synairgen phase II study making encouraging progress
The company is trialling an inhaled interferon beta treatment in lung disease patients who are also suffering from either a cold or flu
Investments and investor services
FTSE 100 closes higher despite continued trade worries
The UK's blue-chip benchmark added over 23 points to close at 7,184
Archive
US jobs data, ECB policy decision to make for up meagre flow of corporate news in coming week
Asides from the macro news, the Week Ahead also brings the latest quarterly FTSE indexes reshuffle, a strategy update from insurer Aviva, and results from Auto Trader
Archive
Proactive news snapshot: ANGLE, Galantas Gold, SkinBioTherapeutics …
A glance at some of the day's highlights from the Proactive Investors newswire
Archive
Proactive news snapshot: NetScientific, Capital Drilling, Horizonte Minerals …
A glance at some of the day's highlights from the Proactive Investors newswire
Archive
RedT Energy Storage shares plunge as it announces strategic review and equity raise
A look at some of the top risers and fallers in London on Thursday.
Synairgen to include more severe COPD patients in phase II SNG001 study
Regulators have given Synairgen the green light to include more severe COPD sufferers in the phase II trial of its SNG001 inhaler following a successful interim safety review
Archive
FTSE 100 closes higher as no deal Brexit fears ease
Footsie closed around 26 points higher at 7,185, while FTSE 250 added around 103 points at 19,283
Synairgen making headway
The company has been developing a treatment for chronic lung disease in-house and has partnered with an Australian group to develop a drug for rare liver and lung complaints
Archive
Proactive news snapshot: Tekcapital, Summit Therapeutics, Widecells …
A glance at some of the day's highlights from the Proactive Investors newswire
Investments and investor services
Mirror and Express newspapers owner Reach rises after increase in adjusted profits
A look at the day's major movers, including IOG, Diurnal, Audioboom, RTC, Baron Oil, United Oil & Gas, Reabold Resources, Andalas Energy, DeepMatter and Fusion Antibodies
Synairgen prelims chart a year of progress
"We look forward to continued progress in 2019," said chairman Simon Shaw.
Investments and investor services
FTSE 100 closes higher but only just as sentiment boosted by trade progress
The UK blue-chip index finished around five points ahead at 7,183
Synairgen’s LOXL2 fibrosis drugs ready for phase II trials
With the receipt of long-term toxicity results, Synairgen and Pharmaxis now have all the data they need to take to potential partners
Archive
Proactive news snapshot: ECSC Group, AFC Energy, Shanta Gold, Iofina PLC …
A glance at some of the day's highlights from the Proactive Investors newswire
Archive
Proactive news snapshot: Hemogenyx, WideCells, Feedback, Synairgen …
A glance at some of the day's highlights from the Proactive Investors newswire
Symphony Environmental surges on UK government plastics ban plans
Some of the main news-driven risers and fallers in London on Monday …
Synairgen kicks off part two of phase II COPD study
The aim of part two is to study the efficacy and safety of the SNG001 inhaler in up to 120 COPD patients with a confirmed respiratory viral infection
FTSE 100 finishes lower as trade worries rear their head again
The UK's premier index of leading shares closed down seven points, or 0.10% at 7,042
Synairgen expands mid-stage COPD study as it raises £2.9mln from investors
The drug developer had originally to recruit 80 people for the second part of its phase II study of its SNG001 treatment, but it will now assess 120 patients